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Saudi Journal of Ophthalmology (2012) 26, 385–392Oculoplastic Imaging UpdateUpdate on advanced imaging options for thyroid-associated orbitopathyMichael P. Rabinowitz, MD; Jacqueline R. Carrasco, MD ⇑AbstractThyroid-associated orbitopathy (TAO) is a diverse spectrum of signs and symptoms that appears to have immunologic and path-
ologic causative factors as diverse as its clinical presentations. Lymphocytes, hormones, and cytokines affect orbital fibroblasts and
other similar cells, which exert their effects on orbital tissues, including the extraocular muscles, orbital fat, and optic nerve. This
complicated inflammatory cascade and the myriad of clinical findings that result contributes to the active phase of TAO. The dis-
tinction between the active and inactive phases of TAO is an important one, as the proper treatment will depend on the disease
phase and degree thereof. Several clinical grading scales and scores have been established to help qualify and quantify the disease
severity. Aiding clinical exam and acumen, proper and reproducible imaging of the orbit and ocular adnexa is incredibly important
to the management of TAO. Orbital ultrasound, computed tomography, magnetic resonance imaging, and scintigraphy each have
unique abilities, including quantifying orbital changes, assessing disease activity, correlating orbital findings with clinical changes,
guiding appropriate treatment, and monitoring therapeutic responses. Further, study ease, accessibility, cost, sensitivity, specific-
ity, reproducibility, and risks are all important considerations in picking the right test with which to diagnose and follow TAO. This
analysis will provide a review of orbital imaging for TAO, including the mechanism of each imaging technique as well as their ratio-
nales, advantages, disadvantages, and utilities.
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Thyroid-associated orbitopathy (TAO), also referred to as
Graves’ ophthalmopathy, Graves’ orbitopathy, and thyroid
eye disease, is a constellation of signs and symptoms result-
ing from chronic autoimmune-related orbital inflammation.
Through extensive investigations into its etiology, many
immunologic and pathologic causative factors have been re-
vealed. Genetic and environmental factors have been related
both to TAO susceptibility as well as to prognosis and re-
sponse to treatment.1 On an immunologic level, the extraoc-
ular muscles and orbital fat have been found targeted by T
lymphocytes and mast cells in association with interferon,
tumor necrosis factor, somatostatin, and interleukin activ-
ity.1–4 At a cellular level, orbital fibroblasts proliferate inPeer review under responsibility
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abnormal amounts of prostaglandins and hyaluronan, which
may increase the orbital volume.1,2,5–7 While the accumula-
tion of this high-molecular-weight compound may be respon-
sible for the orbital changes characteristic of TAO,
gangliosides have also been shown to potentially contrib-
ute.8 Even the role of autoantibodies targeting thyrotropin
receptors remains unclear,1,2,9–11 with other autoimmune
targets such as calequestrin and collagen XIII being re-
searched.9,12 As a result, the correlation between TAO and
Graves’ disease is not a straightforward one.
As many as 50% of patients with Graves’ disease, a form of
hyperthyroidism in which autoantibodies stimulate the
thyrotropin receptor, will develop orbital changes.1,8,13–15
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euthyroid and hypothyroid patients up to 10% of the
time.1,13,15 Except for these comparatively rare cases, the
diagnosis of hyperthyroidism and TAO usually occurs within
18 months of each other.16,17 The incidence of TAO tends
to show a bimodal peak, with the first peak between 40
and 50 years of age and the second occurring between 60
and 70 years of age, and occurs in women about 10 times
more frequently than in men.16–19
The signs and symptoms of TAO are as varied as the path-
ophysiology and epidemiology of the disease. Symptoms
range from tearing to eye pain to double vision, and signs ex-
tend from conjunctival injection and chemosis to lid retrac-
tion and exposure keratopathy to strabismus patterns
(Fig. 1). While approximately half of patients with Graves’
disease are asymptomatic from an ophthalmic standpoint,
20–30% of patients with orbital and ocular involvement are
so affected they require targeted therapies.20,21 And while
Rundle’s curve first introduced the accepted course of TAO
as one of an active, inflammatory phase followed by a static,
fibrotic phase, the exact rate and duration of disease phases
may be as varied and unpredictable as the disease itself.1,20
The distinction is important, though, as one would not want
to operate on actively inflamed muscles, nor would radiation
be indicated in fibrotic disease.
Ultimately, up to 5% of patients with TAO will suffer se-
vere, vision-threatening forms of the disease, including com-
pressive optic neuropathies.16,17 Compounding these
disfiguring, disabling, and painful potential manifestations
of TAO, extensive research has documented the profound ef-
fects this disease has on the mental health and quality of life
of those that endure it.22–24
Several different classification systems have been devel-
oped to assess the varied effects of Graves’ disease on the
eye and orbit. Werner, in 1969, first introduced the well-
known NOSPECS classification; a summary of signs and
symptoms further modified in 1977, this system categorizes
TAO patients in six different classes.25,26 This classification
system is still used today, although minor changes in clinical
disease, as well as active and quiescent phases of TAO, are
difficult to distinguish with NOSPECS criteria. In 1989 Mourits
et al. developed a clinical activity score (CAS), a 10-point sys-
tem that combines symptoms and signs of TAO in a way that
is perhaps more useful in following prognosis and response
to treatment, as well as being theoretically easier to perform
in a primary-care or endocrinologist’s office setting.27–29
More recently, the European Group on Graves’ Orbitopa-
thy (EUGOGO) classified TAO itself in terms of severity,
establishing mild, moderate-to-severe, and sight-threatening
groups,30 a classification system that gave way to referralFigure 1. External photograph of TAO patient with exophthalmos and
ocular misalignment.indications and treatment protocols.20,30 Whether a wait-
and-see approach is established for a mild case of TAO, glu-
cocorticoids used in moderate disease, or orbital decompres-
sion used for severe cases, TAO patients must be followed
and treated based on disease severity and activity.20,29,30 This
is particularly true since the establishment of a euthyroid
state is important in the course of most patients with Graves’
disease and TAO, and treatment with radioiodine therapy
may develop worsening orbitopathy up to 15% of the
time.30,31
As a result of the vast spectrum of etiologies, associations,
signs, symptoms, treatments, and clinical courses presented
by TAO, proper and reproducible imaging of the orbit and
ocular adnexa is incredibly important to its management.
And, from a diagnostic standpoint, disorders such as idio-
pathic orbital inflammatory syndrome (IOIS), metastases, si-
nus inflammations or tumors, carotid-cavernous sinus
fistulas, orbital sarcoid, and lymphoma must be ruled out.
In 1998 members of the European Thyroid Association
reported that most centers used orbital ultrasound (US) in
combination with computed tomography (CT) or magnetic
resonance imaging (MRI) to this capacity, while smaller per-
centages used CT and MRI together or octreotide scanning
with either CT or MRI.32,33 Ease, accessibility, cost, sensitivity,
specificity, reproducibility, and risks are all important consid-
erations in picking the right test with which to diagnose and/
or follow TAO patients. Those matters are discussed in this
review.
Ultrasound
Standardized orbital echography is an old and widely-used
imaging modality that uses reflected high-frequency (8 MHz)
sound waves to form A-scans, supplement them with B-scans,
and incorporates Doppler sonography to measure, differenti-
ate, and elucidate the vascularity of a wide array of orbital le-
sions.33–36 A basic orbital US screens the orbital fat, evaluates
and measures the extraocular muscles, and assesses the optic
nerves.35 Targeted exams include topographic echography in
which a mass may be isolated on the B-scan and then its
dimensions were measured using the A-scan, 30 tests to
evaluate the subarachnoid optic nerve fluid versus inflamma-
tion, quantitative evaluation in which the A-scan uses sonar
reflectivity to evaluate a lesion’s tissue properties, and kinetic
echography during which the physical pressure of the probe is
used to characterize the compressibility of a lesion in ques-
tion.35,37 As a result, the transocular and orbital use of A-scan,
B-scan, and Doppler US has persevered as a fast, inexpensive,
and valuable tool in the evaluation of TAO.34,38,39
Studies investigating US in TAO demonstrated that extra-
ocular muscle thickness, as measured via A- and B-scans, in-
creases with increasing disease severity.39 There is also a
high degree of correlation between the right and left eyes,
the symmetry of which is valuable in distinguishing TAO from
other similar but often unilateral diagnostic entities, such as
IOIS and lymphoma.38,39 Extraocular muscle thickness dem-
onstrated on US has been shown to correlate with the degree
of proptosis as well.40 In fact, Werner et al. demonstrated
that extraocular muscle enlargement is detected by US with
more sensitivity than by clinical exam.38 Additionally, other
sonographic studies of TAO contributed that a significant
association between proptosis and the volume of extraocular
muscle and orbital fat exists.41
Figure 2. Axial orbital CT of TAO with severe fusiform medial rectus
enlargement.
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vealed by echography as well; A-scan measurements have
shown significantly lower extraocular muscle reflectivity in pa-
tients that respond to TAO therapy, indicating that tissue
reflectivity is a marker of edema, inflammation, and disease
activity.42 Studies supportive of US cite this as an advantage
over CT, which provides an excellent anatomic perspective
but cannot evaluate disease activity.43
Prummel et al. followed reflectivity in the extraocular mus-
cles with the lowest echogenecity and found that, after a cut-
off value (40%) was assigned, reflectivity under this value had
a positive predictive value (PPV) for response to TAO treat-
ment of 73%. The negative predictive value (NPV) of tissue
reflectivity over 40% was 100%.42 Contrastingly, a more re-
cent publication by Prummel et al. shows significantly lower
predictive values.44 However, even though extraocular mus-
cle reflectivity may not correlate with CAS, when a CAS over
4/10 is combined with US reflectivity the PPV and NPV for re-
sponse to treatment are 74% and 72% respectively, which rise
to 79% and 89% when the duration of eye symptoms is added
to these clinical parameters.45 Given-Wilson et al. reported
that the medial rectus muscle width itself correlated with clin-
ical score, as well as with CT measurements for the same mus-
cle.46 Similarly, several studies support orbital US as not only
an accurate means of diagnosing TAO pathology and predict-
ing its clinical course, but as a way to follow the course of the
disease and the response to treatment as well.47,48
The addition of color Doppler imaging to US in TAO also
aids its diagnosis, as blood flow measurements in the oph-
thalmic artery, central retinal artery, and central retinal vein
have all been correlated with extraocular muscle diameter
and TAO.49 Further, these blood flow parameters measured
sonographically correlate with CAS levels, and may contrib-
ute to the distinction of active versus inactive disease.50
Reversal and reduction of blood flow through the superior
ophthalmic vein may independently be a sign of severe orbi-
topathy and progression to optic neuropathy.51,52
Ultrasound use in the diagnosis, prognosis, and monitor-
ing of TAO is not without its shortcomings, however. The
orbital apex may be poorly visualized.39 US alone may be
inadequately diagnostic, and may not differentiate TAO from
other causes of large muscles.38 Additionally, although many
of the above references showed positive and encouraging re-
sults using US in TAO, they have also reported a wide range
of average muscle widths and volumes with little consistency
from study to study.39,40,42,47 In several studies looking at US
in TAO the superior rectus is the largest muscle group40,42;
Shammas et al. explain that the superior rectus and superior
oblique tendons may be measured as one on US, further con-
fusing orbital measurements.53 Moreover, the user-depen-
dent nature of sonographic imaging may be detrimental to
study consistency and reproducibility.39 Extraocular muscle
cross-sections are oval rather than round, with their maximum
coronal volume occurring over a fixed area, making it difficult
for a radiologist or ultrasound technician to reproduce the
same angle and location along a muscle for serial
measurements.33
As such, average extraocular muscle sizes in many of the
aforementioned studies also differ from those taken via CT
and MRI.54,55 In the end, while a fast, inexpensive study with
no risks of contrast or radiation, US must be interpreted with
caution given the variability and inconsistency with which itmeasures extraocular muscle sizes, particularly compared to
MRI.56,57 The larger the muscle, the greater the possibility
that US will underestimate its size compared to MRI.55 And,
with regard to CT, US is comparably ineffective in imaging
the posterior orbit, bony anatomy thereof, and optic
nerve.33,34,56Computed tomography
Computed tomography (CT) is an invaluable imaging
modality in the evaluation of TAO, using X-rays and their var-
iable absorptions within the many orbital structures to quan-
tify and qualify orbital pathologies. Orbital fat and water, for
example, absorb less X-rays than higher-density structures
such as the optic nerve and orbital bone. As a result, fat
and water appear hypodense, or darker, than bone and
nerve. Additionally, orbital fat is less dense than water;
resultant differences in orbital tissue densities allow for
high-resolution imaging even without intravenous contrast
administration. Contrast is oftentimes reserved, then, for
cases of optic nerve pathology or vision loss.33,34,58–60
The resolution and diagnostic utility of CT have consis-
tently evolved with the ability of modern scans to apply spiral
techniques and evaluate thin, often less than 1.5 mm, cuts of
the orbital space. The ability to correlate extraocular muscle
changes with the pathology of TAO became a useful utility of
CT, demonstrating swollen muscle bellies with tendon spar-
ing radiographically61 (Fig. 2). Early studies supporting CT
in TAO used larger cuts and found that, while the medial
and lateral rectus muscles were identifiable and quantifiable
at the mid-orbital level, oblique muscles could not be iso-
lated and, unless markedly enlarged, the vertical rectus mus-
cles could not be accurately evaluated.62 Still, although
superior orbital and apical CT cuts were indistinct in earlier
studies, there was high intra-observer consistency on mid-
orbital views with a 66% diagnostic accuracy for TAO.62 Up
to 80% of TAO patients were found to have lateral rectus
enlargement in studies using early imaging, while 77% had
medial rectus enlargement; these data are inconsistent with
reproducible percentages based on more modern CT and
MRI values, many of which show inferior rectus enlargement
more commonly than medial rectus enlargement, followed
by superior pathology and then lateral rectus enlarge-
ment55,63–65 (Fig. 3).
Investigating this, Nugent et al. reviewed orbital CTs of
non-TAO patients and found the average extraocular muscle
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tus > superior muscle group (superior rectus and levator
complex) > lateral rectus.54 The muscle enlargement ratios,
calculated by dividing the average muscle diameters of
TAO orbits from those of normal orbits, found that the supe-
rior muscle group was most often involved by TAO, followed
by the medial rectus, the inferior rectus, and finally the lateral
rectus. However, the average diameters for TAO patients
with and without optic neuropathies, while significantly larger
than those taken from normal orbits, maintained infe-
rior > medial > superior > lateral relationships. Nugent et al.
theorize that the inferior rectus is often the most commonly
clinically and radiographically involved extraocular muscle
because it is the largest at baseline, whereas the superior
muscle group is actually most involved in dysthyroid orbits.54
Studies suggest that while there is an increase in total extra-
ocular muscle volume with increasing clinical ophthalmopa-
thy and increased inferior rectus and orbital fat volumes in
all TAO, the superior rectus size increases only in advanced
disease.66 Medial and lateral rectus muscles may also corre-
late directly with clinical disease.
CT as a tool to quantify muscle enlargement, similar to A-
scan US previously described, is therefore a valuable aid to
the clinical exam. Studies suggest parallels between total
extraocular muscle volumes and medial rectus muscle width
at the mid-orbital level, and medial rectus muscle width with
clinical extraocular muscle restriction, periorbital edema, and
optic neuropathy in those with TAO.67–69 In further correlat-
ing simple CT measurements with optic neuropathy in TAO,
coronal images taken at the mid-point of the orbit were used
by Barrett et al. to create a muscular index (MI).65 The sum of
the vertical rectus muscle width divided by the orbital height
quantifies the vertical MI, and the sum of the horizontal rec-
tus muscle width divided by the orbital width is the horizontal
MI; the larger MI was correlated with clinical findings. MI cut-
offs may be tailored to accommodate clinical goals, as lower
percentages have higher sensitivities and higher percentages
have increased specificities for optic neuropathy. Barrett
et al. found no neuropathy subjects had an MI less than
50%, and no negative cases had an MI over 67%. Giaconi
et al. found an MI over 50% has a sensitivity of 100% for
TAO optic neuropathy, but only 47% specificity.70 A study
by Monteiro et al. revealed sensitivities of 100% for MI values
of 40–50% with decreasing specificities in that range, and a
sensitivity of 32% with a specificity of 100% for an MI of
70%. An MI of 60% was 79% sensitive and 72% specific for
TAO optic neuropathy, and is therefore the best data point
for clinical correlation.71
In looking at changes to and around the optic nerve as
markers of optic neuropathy, grading scales from 0 to 3 wereFigure 3. Coronal orbital CT of TAO showing extraocular muscle
enlargement with relative sparing of the lateral rectus muscles.created by Nugent et al. to describe the percentage of
effacement of perineural fat planes caused by extraocular
muscles as markers of nerve crowding.54 Grade 3 crowding,
or over 50% effacement, correlated with TAO optic neurop-
athy over 66% of the time.54,70 Anterior displacement of
the lacrimal gland has been associated with optic neuropa-
thy, and posterior herniation of the orbital fat is 94% sensitive
and 91% specific for TAO optic neuropathy, with a PPV of
69% and a NPV of 98%.54,70,72
Unlike US and MRI, CT cannot assess disease activity and
involves radiation. CT, however, remains a fast, available, rel-
atively inexpensive test that is highly reproducible.33,34
Although its assessment of the optic nerve itself is less spe-
cific than that of MRI, orbital findings seen on CT are highly
diagnostic and may be directly correlated with optic neurop-
athy and a myriad of other clinical changes. And while CT’s
ability to assess bony anatomy is distinctly advantageous in
correlating clinical changes with imaging characteristics, its
utility in the pre-operative setting, in preparation for orbital
decompression, is invaluable.
Magnetic resonance imaging
In magnetic resonance imaging (MRI), a set of supercon-
ducting coils polarizes a given field by magnetizing certain
nuclei.73 That magnetization depends on protons, positively
charged particles that are constantly rotating, producing an
electric current that gives rise to a magnetic field. Protons
and electrons are normally atomically balanced, and no net
magnetic field is generated. However, several nuclei form
magnetic isotopes containing an odd number of nucleons;
the hydrogen proton is the most common biologic example,
and these unpaired protons generate the signal read on
MRI.33,34,73 Still, random rotation of protons normally exerts
no net magnetic charge; when MRI polarizes the field those
axes align, and an electromagnetic radio-frequency wave
acts on the protons, raising them to an even higher energy
level. T1 and T2 relaxation times refer to the longitudinal
relaxation times and transverse relaxation times, respectively,
of these charged particles after the excitatory wave is discon-
tinued.33,34,73 Variations of those signals provide information
on tissue structure and composition and, as a result, are
uniquely helpful in the diagnosis and monitoring of TAO.
Similar to US, MRI aids in the diagnosis of TAO activity.
MRI is more sensitive and specific in detecting extraocular
muscle enlargement than US, however, particularly when
muscles are markedly enlarged55 (Fig. 4). And while con-
trast-enhancement of the extraocular muscles on MRI may
or may not be of prognostic value compared to clinical
assessment,74,75 longer T2 relaxation times are indicative of
edema and inflammation independent of muscle size55 (Figs.
5 and 6). Nagy et al. found that T2 relaxation times on MRI
provided more diagnostic and prognostic information than
11 clinical and laboratory factors.55
T2 relaxation times as markers of TAO active phases are
valuable tools, both in the selection of proper therapy as well
as for the prediction and monitoring of treatment response.76
Just et al. report decreasing T2 relaxation times in the extra-
ocular muscles of active TAO patients in response to orbital
radiation, and Hosten et al. showed similar signal intensity
changes after immunosuppression.76,77 Hiromatsu et al. cor-
related increased signal intensity ratio on short T1 inversion
recovery sequencing to be indicative of activity and a marker
Figure 4. Axial post-contrast T1 MRI of TAO demonstrating horizontal
rectus muscle enlargement.
Figure 5. Coronal post-contrast T1 MRI of TAO showing marked
enlargement of extraocular muscles on the right side.
Figure 6. External photograph of TAO demonstrated radiographically in
Fig. 5.
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tion times of the extraocular muscles in response to cyclo-
sporine and corticosteroid therapy occur even in spite of
unchanged laboratory markers during and after treatment.79
A lack of correlation between muscle changes on MRI and
thyroid function testing is confirmed elsewhere.80
For further clinical implications, just as CT can effectively
aid the diagnosis of TAO-related optic neuropathy, MRI is a
useful tool in examining pressure on the optic nerve. MRI
examines the optic nerve dimensions itself, though, and does
so with greater accuracy than US.81 MRI has demonstrated a
reproducible decrease in mean nerve diameter as it extends
posterior from the globe, and some report this decrease up
to the orbital apex81,82 while others report a minimum diam-
eter 15 mm posterior to the globe with gradual enlargement
thereafter.83 That ability to quantify the nerve itself has trans-
lated to optic neuropathy in TAO, in which the optic nerve
diameter at the orbital apex has been found significantly re-
duced on MRI.83 This is true even in optic neuropathy orbits
without increased muscle indices.Although its use is limited by long exam time, expense,
availability, and magnetism contraindicated in patients with
certain implants, MRI remains a valuable tool in the care of
TAO. It provides remarkable images of orbital anatomy, ex-
cept for bony structures, particularly at the orbital apex
where resonance may degrade CT images.34,73 Its ability to
quantify muscle enlargement supersedes that of US and
probably CT, and MRI’s comparatively precise and reproduc-
ible capability to qualify disease stage and activity makes it a
unique tool in determining proper treatment and monitoring
therapeutic response.Somatostatin receptor scintigraphy
Somatostatin, a neuroendocrine hormone, has receptors
on many human cells, including fibroblasts, myoblasts, and
lymphocytes which, we have seen, contribute to the pathol-
ogy of active TAO. Octreotide, and several peptide analogs
thereof, has been developed as a longer-acting somatostatin
analog labeled with indium.84 While the intravenously admin-
istered dose and time interval are non-standardized33, this
radionuclide has been shown to accumulate within the orbit
of active TAO patients, is detected via single-photon emis-
sion CT (SPECT), and may serve as a unique marker of dis-
ease activity as a result.84–93
In this way, orbital scintigraphy is quite similar to T2 relax-
ation times on MRI in assessing disease activity, with signifi-
cant correlations being documented radiographically.85
Orbital increase of somatostatin analogs has been found to
correlate well with CAS and clinical disease severity.4,84,86–88
In contrast, the NOSPECS classification has been shown in
some studies to correlate with somatostatin receptor tracer
uptake, while not in others.4,86
Nevertheless, as a result of its clinical associations, scintig-
raphy in TAO may guide treatment by identifying and grad-
ing disease activity.84,85 Gerding et al. specify that
octreotide uptake measured 4 h after injection can predict
the response to radiation treatment with a PPV of 92% and
a NPV of 70% for a given cut-off orbital uptake ratio, whereas
imaging 24 h after octreotide administration is less useful.89
Octreotide uptake has also served as a marker of treatment
effectiveness, decreasing in those undergoing corticosteroid
and somatostatin analog therapy.84,87
Thus, the main utility of orbital octreotide scintigraphy in
TAO seems to be the prediction of those who will benefit
from immunosuppressive or hormonal therapy.33,90–92
Further studies have shown PPVs of 87–90% and NPVs of
up to 100% for octreoscan in the prediction of response to
somatostatin analog therapy,90,92,93 with sensitivities and
specificities of 94% and 100%, respectively, after certain up-
take cutoffs on imaging were established.84 It is limited, how-
ever, by its high cost, inter-observer variance, radiation, lack
of diagnostic specificity for the inflammatory cells it targets or
the surrounding orbital structures, and poor availability.33,90Conclusion
The available imaging modalities in the evaluation and
management of TAO are varied, each one having advanta-
ges, disadvantages, and particular utilities. Orbital US is a
widely used technique that may quantify extraocular muscle
enlargement and inflammation with the added benefits of
390 M.P. Rabinowitz, J.R. Carrascoease, low cost, high accessibility, short exam time, and lack of
radiation. The disadvantages of orbital US include poor visu-
alization of the posterior orbit, inaccuracy in measurements,
and investigator dependence. CT is a fast, easy, inexpensive,
and reproducible study that allows for defined imaging of the
orbital bones, sinuses, and muscles with shortcomings includ-
ing exposure to radiation, lack of correlation with disease
activity and treatment guidance, and poor qualification of
the optic nerve compared to MRI. MRI is an excellent TAO-
imaging modality allowing precise measurements of the
extraocular muscle size, qualification of inflammation, assess-
ment of optic nerve changes, and evaluation of surrounding
orbital and adnexal soft tissue changes without using radia-
tion. However, its high cost, longer exam time, lower avail-
ability, and comparative lack of bony resolution compared
to CT may limit its use. Octreoscan, while a very sensitive test
for inflammation and activity in TAO with an ability to guide
treatment as a result, remains an expensive test suffering
from radiation burden, lack of availability at many institutions,
and inter-observer inconsistency.
The author’s clinical preference in evaluating TAO at the
Wills Eye Institute is CT scanning to assess extraocular muscle
size and shape, apical compression, sinus pathology, and
orbital bone anatomy both as a baseline exam and in the
planning of orbital decompressions or surgeries. We do not
rely on imaging to assess the activity of TAO, but rather
use clinical judgment and serial exams. However, with ad-
vances in MRI and somatostatin receptor scintigraphy, active
disease may be confirmed through imaging, and this may
play an increasing role in our care of TAO patients in the
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